Hadassah

Thrombotech Receives Regulatory Approval for Stroke Medicine Trials in the US

Wednesday, Mar 28 2012

Thrombotech Ltd., a biotechnology company based on cutting-edge stroke research at the Hadassah University Medical Center, has received approval from the United States' Food and Drug Administration (FDA) to expand clinical trials to the US for its lead product, THR-18. This medicine is designed to improve the safety and efficacy of tPA, the currently available treatment for ischemic stroke.

THR-18 is designed to allow tPA to dissolve blood clots easily, extending its short therapeutic time window and diminishing life-threatening side effects. It is currently undergoing Phase IIA clinical trials at several hospitals in Israel, including Hadassah, and is awaiting regulatory approvals in Europe and India.

"This important regulatory approval serves as external validation for our development program and the quality of the science and management behind the company," says Thrombotech Chief Executive Officer Dr. Ruth Ben Yakar. "It will enable us to recruit more patients in some of the leading medical centers specializing in stroke in the US and move towards commercialization of the therapy for this serious medical condition."

Hadasit, Hadassah's technology transfer company, holds a 24% stake in Thrombotech. Commenting on the approval, Ophir Shahaf, Chief Executive Officer of Hadasit Bio-Holdings, Hadasit's publicly traded subsidiary, stated: "We are proud to expand the clinical trial to medical centers in the US, a world leader in Central Nervous System therapeutics and stroke treatment in particular."

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Wednesday, May 23 2018

From Legacy to Innovation: The Vision of Hadassah’s New Division of Nursing Director

Rely Alon, PhD, the new director of the Hadassah Medical Organization’s Division of Nursing and Health Professions, has a vision: “to bring Hadassah’s nurses to the forefront of leadership and to the spearhead of nursing in Israel.”

READ MORE ›
alt_text

Monday, May 7 2018

Hadassah Cardiac Specialists Are Collaborating with Colleagues to Save Syrian Children

In an effort to save the lives of Syrian children suffering from life-threatening and complex heart abnormalities, the Hadassah Medical Organization and the Baruch Padeh Medical Center in Poriya-Tiberias have launched a unique collaboration as part of the Israel Defense Forces’ Good Neighbor program.

READ MORE ›
alt_text

Monday, May 7 2018

Pluristem Stem Cell Therapy, Based on Hadassah Preclinical Research, Has Been Cleared by FDA

Pluristem Therapeutics has announced that its new cell therapy to treat acute radiation syndrome (PLX-R18), based on the pioneering studies performed within the laboratory of Prof. Raphael Gorodetsky at the Hadassah Medical Organization, has received clearance from the United States Food and Drug Administration to treat individuals who may have been acutely exposed to high-dose radiation as the result of a nuclear attack or accident.

READ MORE ›
alt_text

Thursday, May 3 2018

HMO Exclusive Call with Nurse Rely Alon

Please join us for an exclusive conference call with Dr. Rely Alon, Director, Division of Nursing & Health Professions, Wednesday May 9, 2018 from 10:00 - 11:00 am EDT

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More